A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

Trial Profile

A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Methylprednisolone (Primary) ; Prednisolone (Primary) ; Ruxolitinib (Primary)
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Acronyms REACH-1
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 15 Feb 2018 According to an Incyte Corporation media release, the Company expects to submit an sNDA seeking approval of ruxolitinib in this indication.
    • 16 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 30 Dec 2017 According to an Incyte Corporation media release, the first patient has been treated in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top